Advanced Search

 

Study ID Status Title Patient Level Data
AZA30006 Completed A prospective, randomized, double-blind, parallel group study to compare the adjunctive effect of telmisartan with existing antihypertensive therapy in patients with essential hypertension that is uncontrolled on current therapy.
AZA30012 Completed An open label randomized study of efficacy and safety of telmisartan administered during 12 weeks in combination and as sequential single therapy (TEAM study).
AZA30013 Completed Comparison, with self measurements of blood pressure, of residual efficacy of telmisartan and perindopril in mild to moderate essential hypertension (EVERESTE study).
AZA30015 Completed P.R.O.B.E. (Prospective, Randomized, Open-label, Blinded Endpoint) multicentre, parallel-group study to evaluate the efficacy of telmisartan 40/80 mg vs losartan 50/100 mg in patients with mild/moderate hypertension
AZA30016 Completed P.R.O.B.E. (Prospective, Randomized, Open label, Blinded Endpoint) multicentre, parallel group study to evaluate the efficacy of telmisartan 40/80 mg vs lisinopril 10/20 mg in the reduction of progressive renal impairment in hypertensive subjects with type 2 diabetes.
AZA30020 Completed Acute effects of the Angiotensin 1 receptor blockade, telmisartan 80 mg, on the nitric oxide flow-mediated vasodilation of radial artery, in healthy volunteers
AZA40052; AZA40053 Completed Telmisartan Therapy for Hypertension in a Primary-Care Setting: A Canadian Observational Study
AZL10001 Completed An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption i ...
AZL10002 Completed An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 ...
AZL30002 Completed A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL)
AZL30004 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30004_1 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30006 Completed A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.
AZL40001 Completed An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment)
AZLF3002 Completed Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of Trizivir, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne).
AZLF3004 Completed An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud
B04-689PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.
B04-696PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.
B2A10001 Completed A randomised, double blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled doses of a new chemical entity in healthy male subjects. Study Listed on ClinicalStudyDataRequest.com
B2A10002 Completed A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics of single inhaled dose of a new chemical entity in asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
B2B10001 Completed A randomised, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of GW678007 in healthy male subjects. Study Listed on ClinicalStudyDataRequest.com
B2B10002 Completed A multi-centre, randomized, double-blind, double dummy, placebo-controlled, 5-period crossover study to examine the safety, tolerability, systemic pharmacodynamics, and systemic pharmacokinetics of single inhaled doses of a new chemical entity in asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
B2C10001 Completed A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C101762 Completed A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C104604 Completed A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.